Northern Trust’s Voyager Therapeutics VYGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.44M | Buy |
411,803
+26,960
| +7% | +$102K | ﹤0.01% | 3317 |
|
|
2026
Q1 | $1.49M | Buy |
384,843
+16,297
| +4% | +$64.2K | ﹤0.01% | 3129 |
|
|
2025
Q4 | $1.45M | Sell |
368,546
-26,205
| -7% | -$116K | ﹤0.01% | 3181 |
|
|
2025
Q3 | $1.84M | Sell |
394,751
-9,731
| -2% | -$35.2K | ﹤0.01% | 3079 |
|
|
2025
Q2 | $1.26M | Sell |
404,482
-7,537
| -2% | -$24.3K | ﹤0.01% | 3261 |
|
|
2025
Q1 | $1.39M | Sell |
412,019
-6,726
| -2% | -$31.4K | ﹤0.01% | 3120 |
|
|
2024
Q4 | $2.37M | Buy |
418,745
+12,374
| +3% | +$79.8K | ﹤0.01% | 2927 |
|
|
2024
Q3 | $2.38M | Buy |
406,371
+32,210
| +9% | +$234K | ﹤0.01% | 2894 |
|
|
2024
Q2 | $2.96M | Sell |
374,161
-15,655
| -4% | -$131K | ﹤0.01% | 2684 |
|
|
2024
Q1 | $3.63M | Buy |
389,816
+74,850
| +24% | +$632K | ﹤0.01% | 2662 |
|
|
2023
Q4 | $2.66M | Buy |
314,966
+12,195
| +4% | +$88.5K | ﹤0.01% | 2840 |
|
|
2023
Q3 | $2.35M | Buy |
302,771
+6,651
| +2% | +$60.7K | ﹤0.01% | 2853 |
|
|
2023
Q2 | $3.39M | Buy |
296,120
+210,133
| +244% | +$2.17M | ﹤0.01% | 2714 |
|
|
2023
Q1 | $663K | Buy |
85,987
+2,379
| +3% | +$18.9K | ﹤0.01% | 3349 |
|
|
2022
Q4 | $510K | Buy |
83,608
+6,608
| +9% | +$37.5K | ﹤0.01% | 3504 |
|
|
2022
Q3 | $456K | Buy |
77,000
+2,192
| +3% | +$14K | ﹤0.01% | 3547 |
|
|
2022
Q2 | $442K | Sell |
74,808
-4,311
| -5% | -$29.1K | ﹤0.01% | 3579 |
|
|
2022
Q1 | $603K | Buy |
79,119
+1,683
| +2% | +$7.51K | ﹤0.01% | 3668 |
|
|
2021
Q4 | $209K | Buy |
77,436
+2,653
| +4% | +$9.05K | ﹤0.01% | 4182 |
|
|
2021
Q3 | $197K | Sell |
74,783
-9,512
| -11% | -$30.9K | ﹤0.01% | 4191 |
|
|
2021
Q2 | $348K | Sell |
84,295
-228,661
| -73% | -$1.04M | ﹤0.01% | 3868 |
|
|
2021
Q1 | $1.47M | Sell |
312,956
-40,471
| -11% | -$276K | ﹤0.01% | 3411 |
|
|
2020
Q4 | $2.53M | Sell |
353,427
-8,576
| -2% | -$82.4K | ﹤0.01% | 3078 |
|
|
2020
Q3 | $3.86M | Sell |
362,003
-14,736
| -4% | -$173K | ﹤0.01% | 2697 |
|
|
2020
Q2 | $4.75M | Buy |
376,739
+32,508
| +9% | +$378K | ﹤0.01% | 2557 |
|
|
2020
Q1 | $3.15M | Buy |
344,231
+8,373
| +2% | +$96.1K | ﹤0.01% | 2582 |
|
|
2019
Q4 | $4.68M | Sell |
335,858
-195
| -0.1% | -$2.83K | ﹤0.01% | 2620 |
|
|
2019
Q3 | $5.78M | Buy |
336,053
+40,126
| +14% | +$842K | ﹤0.01% | 2463 |
|
|
2019
Q2 | $8.05M | Buy |
295,927
+15,175
| +5% | +$347K | ﹤0.01% | 2286 |
|
|
2019
Q1 | $5.37M | Buy |
280,752
+5,712
| +2% | +$74.4K | ﹤0.01% | 2522 |
|
|
2018
Q4 | $2.58M | Sell |
275,040
-9,945
| -3% | -$128K | ﹤0.01% | 2906 |
|
|
2018
Q3 | $5.39M | Buy |
284,985
+17,544
| +7% | +$337K | ﹤0.01% | 2641 |
|
|
2018
Q2 | $5.23M | Buy |
267,441
+67,063
| +33% | +$1.33M | ﹤0.01% | 2660 |
|
|
2018
Q1 | $3.77M | Buy |
200,378
+6,276
| +3% | +$136K | ﹤0.01% | 2752 |
|
|
2017
Q4 | $3.22M | Buy |
194,102
+40,606
| +26% | +$696K | ﹤0.01% | 2861 |
|
|
2017
Q3 | $3.16M | Buy |
153,496
+19,925
| +15% | +$225K | ﹤0.01% | 2904 |
|
|
2017
Q2 | $1.2M | Buy |
133,571
+28,222
| +27% | +$284K | ﹤0.01% | 3394 |
|
|
2017
Q1 | $1.4M | Sell |
105,349
-408
| -0.4% | -$4.95K | ﹤0.01% | 3237 |
|
|
2016
Q4 | $1.35M | Buy |
105,757
+220
| +0.2% | +$2.83K | ﹤0.01% | 3264 |
|
|
2016
Q3 | $1.27M | Sell |
105,537
-166
| -0.2% | -$2.25K | ﹤0.01% | 3274 |
|
|
2016
Q2 | $1.16M | Buy |
105,703
+50,713
| +92% | +$621K | ﹤0.01% | 3301 |
|
|
2016
Q1 | $480K | Hold |
54,990
| – | – | ﹤0.01% | 3477 |
|
|
2015
Q4 | $1.2M | Buy |
+54,990
| New | +$1.27M | ﹤0.01% | 3259 |
|
Other funds holding VYGR
AC
VPC
OM
Northern Trust's VYGR Position: Q2 2026 in Review
Northern Trust increased its Voyager Therapeutics (VYGR) stake by 7% in Q2 2026, buying an estimated $102K and bringing the position to 411,803 shares worth $1.44M. The position accounts for ﹤0.01% of the portfolio, ranked #3317.
Northern Trust first reported a position in VYGR in Q4 2015 and has held it in 43 quarters since. The position peaked at $8.05M in Q2 2019. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.
- Northern Trust held 411,803 shares of Voyager Therapeutics worth $1.44M as of Q2 2026.
- Northern Trust bought 26,960 Voyager Therapeutics shares in Q2 2026, an estimated $102K.
- Voyager Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3317 holding.
- Northern Trust first reported a position in Voyager Therapeutics in Q4 2015 and has held it in 43 quarters since.
- Northern Trust's Voyager Therapeutics position peaked at $8.05M in Q2 2019.
- 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.
Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.